Prostate cancer Active Surveillance Study (PASS) Cohort: Infrastructure Support for Cancer Research

项目概要/摘要 我们建议支持已建立的前列腺癌主动监测研究 (PASS) 队列，该研究是一项 大型多机构队列，由患有临床局限性前列腺癌且选择积极治疗的男性组成 监测以控制他们的癌症。具有旨在代表男性人口的广泛资格标准 该队列拥有超过 2,100 名参与者，他们利用主动监测，具有广泛的临床和 流行病学数据（人口统计、生活方式、生活质量、长期结果）和纵向生物样本 （种系 DNA、血清、血浆、尿液和前列腺组织）根据标准化方案收集。的 该队列成立于 2008 年，旨在应对越来越多的前列腺癌过度治疗的证据以及 需要进行前瞻性研究来发现和验证前列腺癌进展的生物标志物，并 确定癌症进展和患者结果的决定因素。在过去的十年里，该群体已经 积累了大量的数据和生物样本，使其成为解决关键问题的基础 与早期前列腺癌最佳个性化管理相关的问题。 该申请的成功资助将为 PASS 提供强大的基础设施支持，从而确保 PASS 数据和样本的可用性有助于解决癌症决定因素的研究 进展、复发和结果。这些研究工作的很大一部分是 包含在当前资助的联邦拨款中，以及当前和未来的成功完成 项目依赖于 PASS 企业的持续成功。该群体的影响力在于其潜力 调查最重要的研究问题：确定更好的前列腺预后标志物 癌症侵袭性；了解早期阶段的临床管理、进展和结果 前列腺癌；根据个人特征定制主动监测方法 偏好；描述临床病理因素、患者生活方式和疾病之间的关联 生物学；开发新工具向患者传达医疗信息；并理解决策- 积极监测患者的情况，特别是在生活质量、焦虑和遗憾方面。 这些变革性研究工作的成功完成将解决大多数未满足的需求 常见诊断男性癌症并大幅减轻当前早期公共卫生负担 前列腺癌。

PROJECT SUMMARY/ABSTRACT We propose to support the established Prostate cancer Active Surveillance Study (PASS) cohort, which is a large multi-institutional cohort of men with clinically localized prostate cancer who have elected active surveillance to manage their cancer. With broad eligibility criteria designed to represent the population of men who utilize active surveillance, the cohort has over 2,100 participants with extensive clinical and epidemiological data (demographic, lifestyle, quality of life, long-term outcomes) and longitudinal biospecimens (germline DNA, serum, plasma, urine, and prostate tissue) collected according to a standardized protocol. The cohort was established in 2008 in response to the growing evidence of prostate cancer overtreatment and the need for a prospective study to discover and validate biomarkers of prostate cancer progression, and to identify determinants of cancer progression and patient outcomes. Over the past decade, the cohort has amassed a wealth of data and biospecimens so that it serves as the foundation for addressing critical questions relevant to the optimal personalized management of early stage prostate cancer. The successful funding of this application will support a robust infrastructure for PASS that in turn will ensure the availability of PASS data and specimens to facilitate research addressing determinants of cancer progression, recurrence, and outcomes. A substantial proportion of these research endeavors are encompassed in currently funded federal grants, and the successful completion of the current and future projects relies on the continued success of the PASS enterprise. The impact of this cohort lies in its potential to investigate research questions of paramount importance: to identify better prognostic markers of prostate cancer aggressiveness; to understand the clinical management, progression and outcomes of early stage prostate cancer; to tailor the approach of active surveillance based on individual characteristics and preferences; to characterize associations between clinicopathologic factors, patient lifestyle, and disease biology; to develop new tools to communicate medical information to patients; and to understand decision- making among patients on active surveillance, in particular with regards to quality of life, anxiety, and regret . The successful completion of these transformative research endeavors will address unmet needs in the most commonly diagnosed male cancer and substantially reduce the current public health burden of early stage prostate cancer.